Gozde Yazici1, Faruk Zorlu2, Mustafa Cengiz1, Gokhan Ozyigit1, Gulnihan Eren1, Deniz Yüce3, Ali Varan4, Canan Akyuz4, Nejat Akalan5, Murat Gurkaynak1. 1. Department of Radiation Oncology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. 2. Department of Radiation Oncology, School of Medicine, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. yazicig@gmail.com. 3. Department of Preventive Oncology, School of Medicine, Hacettepe University, Ankara, Turkey. 4. Department of Pediatric Oncology, School of Medicine, Hacettepe University, Ankara, Turkey. 5. Department of Neurosurgery, School of Medicine, Hacettepe University, Ankara, Turkey.
Abstract
PURPOSE: The aim of this study was to report the outcome in children with high-grade astrocytoma outside the brain stem and spinal cord that were treated at a single center. MATERIALS AND METHODS: The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years. At initial diagnosis, 18 of the patients with glioblastoma received only temozolomide (TMZ), 14 received other chemotherapies, and 5 did not receive any chemotherapy. Among the patients with anaplastic astrocytoma, 9 received TMZ, 9 received other chemotherapy regimens, and 8 patients did not receive any chemotherapy. The median radiotherapy dose in all patients was 60 Gy. RESULTS: Median age of the patients was 12.5 years. Median overall survival was 20 months and mean progression-free survival was 4.7-11.3 months (median: 8 months) in all patients. Patients with a Karnofsky performance score (KPS) ≥70 had median overall survival of 32 months, versus 7 months in those with a KPS < 70. Patients aged <15 years had median survival of 38 months, versus 16 months in those aged 15-18 years. Patients with anaplastic astrocytoma that received TMZ, other chemotherapy regimens, and no chemotherapy had median survival of 21 months, 132 months, and 11 months, respectively. Patients with glioblastoma that received TMZ, other chemotherapy regimens, and no chemotherapy had median survival of 32 months, 12 months, and 8 months, respectively. CONCLUSION: In the present study, patients with anaplastic astrocytoma treated with chemotherapy protocols other than TMZ had the longest OS; however, in the glioblastoma group, OS was 32 months in those treated with standard TMZ and 12 months in those treated with other protocols (P = 0.493). Although TMZ is less toxic than PCV, it was not shown to be superior.
PURPOSE: The aim of this study was to report the outcome in children with high-grade astrocytoma outside the brain stem and spinal cord that were treated at a single center. MATERIALS AND METHODS: The study included 26 patients with anaplastic astrocytoma and 37 patients with glioblastoma; all patients were aged ≤18 years. At initial diagnosis, 18 of the patients with glioblastoma received only temozolomide (TMZ), 14 received other chemotherapies, and 5 did not receive any chemotherapy. Among the patients with anaplastic astrocytoma, 9 received TMZ, 9 received other chemotherapy regimens, and 8 patients did not receive any chemotherapy. The median radiotherapy dose in all patients was 60 Gy. RESULTS: Median age of the patients was 12.5 years. Median overall survival was 20 months and mean progression-free survival was 4.7-11.3 months (median: 8 months) in all patients. Patients with a Karnofsky performance score (KPS) ≥70 had median overall survival of 32 months, versus 7 months in those with a KPS < 70. Patients aged <15 years had median survival of 38 months, versus 16 months in those aged 15-18 years. Patients with anaplastic astrocytoma that received TMZ, other chemotherapy regimens, and no chemotherapy had median survival of 21 months, 132 months, and 11 months, respectively. Patients with glioblastoma that received TMZ, other chemotherapy regimens, and no chemotherapy had median survival of 32 months, 12 months, and 8 months, respectively. CONCLUSION: In the present study, patients with anaplastic astrocytoma treated with chemotherapy protocols other than TMZ had the longest OS; however, in the glioblastoma group, OS was 32 months in those treated with standard TMZ and 12 months in those treated with other protocols (P = 0.493). Although TMZ is less toxic than PCV, it was not shown to be superior.
Authors: Stephanie M Perkins; Joshua B Rubin; Jeffrey R Leonard; Matthew D Smyth; Issam El Naqa; Jeff M Michalski; Joseph R Simpson; David L Limbrick; Tae S Park; David B Mansur Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-08 Impact factor: 7.038
Authors: Kenneth J Cohen; Ian F Pollack; Tianni Zhou; Allen Buxton; Emiko J Holmes; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Ronald L Hamilton; Robert S Lavey; Richard L Heideman Journal: Neuro Oncol Date: 2011-03 Impact factor: 12.300
Authors: Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee Journal: J Neuropathol Exp Neurol Date: 2002-03 Impact factor: 3.685
Authors: R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond Journal: J Neurooncol Date: 1989-07 Impact factor: 4.130
Authors: Federico Sánchez-Herrera; Eduardo Castro-Sierra; Luis Felipe Gordillo-Domínguez; Miguel Angel Vaca-Ruiz; Blanca Santana-Montero; Mario Perezpeña-Diazconti; Vicente González-Carranza; Samuel Torres-García; Fernando Chico-Ponce de León Journal: Childs Nerv Syst Date: 2009-01-16 Impact factor: 1.475
Authors: Johannes E A Wolff; Pablo Hernaiz Driever; Bernhard Erdlenbruch; Rolf D Kortmann; Stefan Rutkowski; Torsten Pietsch; Crystal Parker; Monica Warmuth Metz; Astrid Gnekow; Christof M Kramm Journal: Cancer Date: 2010-02-01 Impact factor: 6.860
Authors: Aleksandra Napieralska; Aleksandra Krzywon; Agnieszka Mizia-Malarz; Joanna Sosna-Zielińska; Ewa Pawłowska; Małgorzata A Krawczyk; Katarzyna Konat-Bąska; Aneta Kaczorowska; Anna Dąbrowska; Maciej Harat Journal: Cancers (Basel) Date: 2021-04-24 Impact factor: 6.639